The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels

Life Sciences

Volumn 197, Issue , 2018, Pages 46-55

  Li, Hongliang ^a   Shin, Sung Eun ^a   Seo, Mi Seon ^a   An, Jin Ryeol ^a   Choi, Il Whan ^b   Jung, Won Kyo ^c   Firth, Amy L ^d   Lee, Dae Sung ^e   Yim, Mi Jin ^e   Choi, Grace ^e   Lee, Jeong Min ^e   Na, Sung Hun ^a   Park, Won Sun ^a  

^a Kangwon National University   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Pukyong National University   (South Korea)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e National Marine Biodiversity Institute of Korea   (South Korea)

Author keywords

Aortic smooth muscle; Dapagliflozin; PKG; Vasorelaxation; Voltage dependent K+ channel

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 9 (TETRAHYDRO 2 FURYL)ADENINE; APAMIN; CYCLIC GMP DEPENDENT PROTEIN KINASE; DAPAGLIFLOZIN; FAMPRIDINE; GLIBENCLAMIDE; GUANYLATE CYCLASE INHIBITOR; KT 5720; KT 5823; N(G) NITROARGININE METHYL ESTER; NIFEDIPINE; NS 2028; PAXILLINE; PHENYLEPHRINE; POTASSIUM CHANNEL; THAPSIGARGIN; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL BLOCKING AGENT; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTIC MEDIA; ARTERY TONE; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM; ENZYME ACTIVATION; MALE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; VASCULAR RING; VASODILATATION; ANIMAL; AORTA; DRUG EFFECTS; LEPORIDAE; METABOLISM; PATHOPHYSIOLOGY; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; BENZHYDRYL COMPOUNDS; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; GLUCOSIDES; HYPOGLYCEMIC AGENTS; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; POTASSIUM CHANNELS, VOLTAGE-GATED; RABBITS; VASODILATION;

EID: 85041582283     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2018.01.032     Document Type: Article

References (31)

1. Thong, K.Y., Yadagiri, M., Bames, D.J., Morris, D.S., Chowdhury, T.A., Chuah, L.L., Robinson, A.M., Bain, S.C., Adamson, K.A., Ryder, R.E.J., ABCD nationwide dapagliflozin audit contributors, Clinical risk factors predicting genital fungal infections with sodium-glucose contransporter 2 inhibitor treatment: the ABCD nationwide dapagliflozin audit. Prim. Care Diabetes, 2017, 10.1016/j.pcd.2017.06.004.
2. Wu, Y., Ding, Y., Tanaka, Y., Zhang, W., Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int. J. Med. Sci. 11 (2014), 1185–1200.
3. Browniee, M., The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005), 1615–1625.
4. Vierling, C., Baumgartner, C.M., Bollerhey, M., Erhardt, W.D., Stampfl, A., Vierling, W., The vasodilating effect of a Hintonia latiflora extract with antidiabetic action. Phytomedicine 21 (2014), 1582–1586.
5. Zargar, A.H., Wani, A.A., Laway, B.A., Masoodi, S.R., Wani, A.I., Bashir, M.I., Dar, F.A., Prevalence of diabetes mellitus and other abnormalities of glucose tolerance in young adults aged 20–40 years in North India. Diabetes Res. Clin. Pract. 82 (2008), 276–281.
6. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J., Broedl, U.C., Inzucchi, S.E., EMPA-REG OUTCOME Investigators, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373 (2015), 2117–2128.
7. Ashjian, E., Tingen, J., Sodium-glucose cotransporter-2 inhibitors: expanding oral treatment options for type 2diabetes mellitus. Nurse Pract. 42 (2017), 8–15.
8. DeFronzo, R.A., Davidson, J.A., Del Prato, S., The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 14 (2012), 5–14.
9. Ptaszynska, A., Hardy, E., Johnsson, E., Parikh, S., List, J., Effects of dapagliflozin on cardiovascular risk factors. Postgrad. Med. 125 (2013), 181–189.
10. Nelson, M.T., Quayle, J.M., Physiological roles and properties of potassium channels in arterial smooth muscle. Am. J. Phys. 268 (1995), 799–822.
11. Jackson, W.F., Ion channels and vascular tone. Hypertension 35 (2000), 173–178.
12. + channel modulation in arterial smooth muscle. Acta Physiol. Scand. 164 (1998), 549–557.
13. Hara, Y., Kitamura, K., Kuriyama, H., Actions of 2-aminopyridine on vascular smooth muscle tissues of the guinea-pig. Br. J. Pharmacol. 68 (1980), 99–106.
14. + channels in vascular smooth muscle cells: modulation by protein kinases. Prog. Biophys. Mol. Biol. 103 (2010), 95–101.
15. Clemens, K.K., Shariff, S., Liu, K., Hramiak, I., Mahon, J.L., McArthur, E., Garg, A.X., Trends in antihyperglycemic medication prescriptions and hypoglycemia in older adults: 2002–2013. PLoS One, 10, 2015, e0317596.
16. Persson, F., Nystrom, T., Jorgensen, M.E., Carstensen, B., Gulseth, H.L., Thuresson, M., Fenici, P., Nathanson, D., Eriksson, J.W., Norhammar, A., Bodegard, J., Birkeland, K.I., Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes. Metab., 2017, 1–8, 10.1111/dom.13077.
17. Kosiborod, M., Gause-Nisson, I., Xu, J., Sonesson, C., Johnsson, E., Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. J. Diabetes Complicat. 31 (2017), 1215–1221.
18. Kleppisch, T., Nelson, M.T., Adenosine activates ATP-sensitive potassium channels in arterial myocytes via A2 receptors and cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 12441–12445.
19. + currents in rabbit arterial smooth-muscle via protein-kinase-A. J. Physiol. 475 (1994), 9–13.
20. ATP channels by 11, 12-epoxyeicosatrienoic acid. Am. J. Physiol. Heart Circ. Physiol. 288 (2005), 358–364.
21. Samuel, S., Zhang, K., Tang, Y.D., Gerdes, A.M., Carrillo-Sepulveda, M.A., Triiodothyronine potentiates vasorelaxation via PKG/VASP signaling in vascular smooth muscle cells. Cell. Physiol. Biochem. 41 (2017), 1894–1904.
22. Lincoln, T.M., Myosin phosphatase regulatory pathways: different functions or redundant functions?. Circ. Res. 100 (2007), 10–12.
23. Butt, E., Abel, K., Krieger, M., Palm, D., Hoppe, V., Hoppe, J., Walter, U., cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J. Biol. Chem. 269 (1994), 14509–14517.
24. Lincoln, T.M., Dey, N., Sellak, H., Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J. Appl. Physiol. 91 (2001), 1421–1430.
25. Beall, A.C., Kato, K., Goldenring, J.R., Rasmussen, H., Brophy, C.M., Cyclic nucleotide-dependent vasorelaxation is associated with the phosphorylation of a small heat shock-related protein. J. Biol. Chem. 272 (1997), 11283–11287.
26. Dou, D., Zheng, X., Ying, L., Ye, L., Gao, Y., Sulfhydryl-dependent dimerization and cGMP-mediated vasodilatation. J. Cardiovasc. Pharmacol. 62 (2013), 1–5.
27. Patel, D., Kandhi, S., Kelly, M., Neo, B.H., Wolin, M.S., Dehydroepiandrosterone promotes pulmonary artery relaxation by NADPH oxidation-elicited subunit dimerization of protein kinase G 1α. Am. J. Phys. Lung Cell. Mol. Phys. 306 (2014), 383–391.
28. Tang, W., Leil, T.A., Johnsson, E., Boulton, D.W., LaCareta, F., Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type1 versus type 2 diabetes mellitus. Diabetes Obes. Metab. 18 (2016), 236–240.
29. Kim, H.W., Li, H., Kim, H.S., Shin, S.E., Jung, W.K., Ha, K.S., Han, E.T., Hong, S.H., Choi, I.W., Firth, A.L., Bang, H., Park, W.S., The anti-diabetic drug repaglinide induces vasorelaxation via activation of PKA and PKG in aortic smooth muscle. Vasc. Pharmacol. 84 (2016), 38–46.
30. + channels in aortic smooth muscle. Cardiovasc. Ther., 2017, e12299, 10.1111/1755-5922.12299.
31. + channels and SERCA pump in aortic smooth muscle. Life Sci. 188 (2017), 1–9.